Cargando…

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232

GSK2838232 (GSK232) is a novel maturation inhibitor that blocks the proteolytic cleavage of HIV-1 Gag at the junction of capsid and spacer peptide 1 (CA/SP1), rendering newly-formed virions non-infectious. To our knowledge, GSK232 has not been tested against HIV-2, and there are limited data regardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Robert A., Raugi, Dana N., Nixon, Robert S., Song, Jennifer, Seydi, Moussa, Gottlieb, Geoffrey S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847912/ https://www.ncbi.nlm.nih.gov/pubmed/36652466 http://dx.doi.org/10.1371/journal.pone.0280568

Ejemplares similares

The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects
por: Johnson, Mark, et al.
Publicado: (2018)

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
por: Smith, Robert A, et al.
Publicado: (2015)

Resource and infrastructure challenges on the RESIST-2 Trial: an implementation study of drug resistance genotype-based algorithmic ART switches in HIV-2-infected adults in Senegal
por: Raugi, Dana N., et al.
Publicado: (2021)

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
por: Dicker, Ira, et al.
Publicado: (2019)

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile
por: Dicker, Ira, et al.
Publicado: (2022)

Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
por: Zhang, Ying, et al.
Publicado: (2023)

Correction: Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
Publicado: (2019)

Infection à VIH-2 au Sénégal: échecs virologiques et résistances aux antirétroviraux (ARV)
por: Ba, Selly, et al.
Publicado: (2019)

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates
por: Ray, Neelanjana, et al.
Publicado: (2017)

Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV
por: Wilkins, Jordan, et al.
Publicado: (2016)

HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
por: Gottlieb, Geoffrey S., et al.
Publicado: (2011)

The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription
por: Okoye, Afam A., et al.
Publicado: (2022)

Dendritic Cells in HIV/SIV Prophylactic and Therapeutic Vaccination
por: Ko, Eun-Ju, et al.
Publicado: (2019)

Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878
por: Wang, Chunfu, et al.
Publicado: (2023)

Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens
por: Smith, Robert A., et al.
Publicado: (2012)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
por: Joshi, Samit R., et al.
Publicado: (2020)

Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Alterations in intracellular potassium concentration by HIV-1 and SIV Nef
por: Choi, Bongkun, et al.
Publicado: (2008)

Maturation of protective immunity induced by SIVΔnef correlates with differential expression of transcription factors in SIV-specific CD8+ T cells
por: Billingsley, JM, et al.
Publicado: (2012)

HIV/SIV vaccine trials database 2007 /
Publicado: (2007)

Innate Lymphoid Cells in HIV/SIV Infections
por: Shah, Spandan V., et al.
Publicado: (2017)

Adipose Tissue T Cells in HIV/SIV Infection
por: Wanjalla, Celestine N., et al.
Publicado: (2018)

Defining HIV and SIV Reservoirs in Lymphoid Tissues
por: Deleage, Claire, et al.
Publicado: (2016)

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Increasing prevalence of hypertension among HIV-positive and negative adults in Senegal, West Africa, 1994-2015
por: Benzekri, Noelle A., et al.
Publicado: (2018)

Correction: Increasing prevalence of hypertension among HIV-positive and negative adults in Senegal, West Africa, 1994-2015
por: Benzekri, Noelle A., et al.
Publicado: (2019)

Dynamics of Immune Escape during HIV/SIV Infection
por: Althaus, Christian L., et al.
Publicado: (2008)

The Fourth Major Restriction Factor Against HIV/SIV
por: Nomaguchi, Masako, et al.
Publicado: (2011)

TRIM5α and Species Tropism of HIV/SIV
por: Nakayama, Emi E., et al.
Publicado: (2012)

CTL Escape and Viral Fitness in HIV/SIV Infection
por: Seki, Sayuri, et al.
Publicado: (2012)

Tetherin antagonism by HIV-1 and its SIV precursors
por: Kirchhoff, Frank
Publicado: (2011)

Macrophage Tropism in Pathogenic HIV-1 and SIV Infections
por: Moeser, Matthew, et al.
Publicado: (2020)

HIV and SIV Envelope Glycoproteins Interact with Glycolipids and Lipids
por: Planes, Rémi, et al.
Publicado: (2023)

Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV
por: Roederer, Mario, et al.
Publicado: (2013)

The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid
por: Zhou, Jing, et al.
Publicado: (2004)

Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors
por: Smith, Robert A, et al.
Publicado: (2010)

GCM-SIV1.5: Optimal Tradeoff between GCM-SIV1 and GCM-SIV2
por: Zhang, Ping
Publicado: (2023)

CCR5 Inhibition Prevents Cardiac Dysfunction in the SIV/Macaque Model of HIV
por: Kelly, Kathleen M., et al.
Publicado: (2014)

Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process
por: Adamson, Catherine S.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t8ju0iutqpd71pujir674vo42p